Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Banyan Biomarkers

Request full access

Banyan Biomarkers | Discovery, Validation, Commercialization of Biochemical Markers

Alachua, United StatesFounded 2002Biotech & Life Sciences

About Banyan Biomarkers

Banyan Biomarkers operates as a biotechnology firm focused on developing and commercializing objective diagnostic solutions for traumatic brain injury (TBI). The company was founded in 2002 as a spin-out from the University of Florida by a team of researchers: Dr. Ron Hayes, an expert in traumatic brain injury; Dr. Kevin Wang, a biochemist; and Dr. Nancy Denslow, a proteomics specialist. Their collective expertise led to the identification of specific protein biomarkers that are released into the bloodstream following a head injury.

The company's core product is the Banyan Brain Trauma Indicator (BTI), a blood test designed to aid in the evaluation of mild TBI, commonly known as concussions. The test measures the levels of two brain-specific protein biomarkers, UCH-L1 and GFAP, which rapidly appear in the blood within 12 hours after an injury. This provides physicians and healthcare providers with objective, quantifiable data to assess the likelihood of intracranial lesions. A significant benefit of the BTI is its ability to help rule out the need for a computed tomography (CT) scan, thereby reducing a patient's exposure to unnecessary radiation and lowering healthcare costs. Clinical studies demonstrated high accuracy, with the test predicting the presence of intracranial lesions on a CT scan 97.5% of the time and the absence of lesions 99.6% of the time.

The development of the BTI was significantly supported by funding from the U.S. Department of Defense, which sought better diagnostic tools for soldiers. A major milestone was achieved in February 2018, when the U.S. Food and Drug Administration (FDA) granted marketing clearance for the Banyan BTI, making it the first blood test approved for the evaluation of mild TBI in adults. This approval came through the FDA's Breakthrough Devices Program, which expedites the review of novel medical devices. The company's business model involves commercializing these proprietary tests for use in in-vitro diagnostics. In 2017, Banyan entered into a strategic partnership with bioMérieux, a global leader in in-vitro diagnostics, which included an equity investment and worldwide commercialization rights. Subsequently, bioMérieux acquired Banyan Biomarkers.

Source: Dealroom company data

Banyan Biomarkers in the Alachua ecosystem

Live from Dealroom

The Banyan Biomarkers office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Anzu Partners
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Alachua HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Banyan Biomarkers on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Banyan Biomarkers on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.